Genetic Analysis in a Familial Case With High Bone Mineral Density Suggests Additive Effects at Two Loci-Reference-Cited by-同舟云学术

Genetic Analysis in a Familial Case With High Bone Mineral Density Suggests Additive Effects at Two Loci

Published:2022-02-18 Issue:4 Volume:6 Page:
ISSN:2473-4039
Container-title:JBMR Plus
language:en
Short-container-title:JBMR Plus

Author:

Martínez‐Gil Núria¹^ORCID,Ovejero Diana²^ORCID,Garcia‐Giralt Natalia²^ORCID,Bruque Carlos David³^ORCID,Mellibovsky Leonardo²,Nogués Xavier²,Rabionet Raquel¹,Grinberg Daniel¹^ORCID,Balcells Susanna¹^ORCID

Affiliation:

1. Department of Genetics, Microbiology and Statistics, Faculty of Biology Universitat de Barcelona, Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), instituto de investigación biomédica básica de la Universidad de Barcelona (IBUB), Institut de Recerca Sant Joan de Déu (IRSJD) Barcelona Spain

2. Musculoskeletal Research Group IMIM (Hospital del Mar Medical Research Institute), Centro de Investigación Biomédica en Red en Fragilidad y Envejecimiento Saludable (CIBERFES), Instituto de Salud Carlos III (ISCIII) Barcelona Spain

3. Unidad de Conocimiento Traslacional Hospitalaria Patagónica Hospital de Alta Complejidad Servicio de Atención Médica Integral para la Comunidad (SAMIC) ‐ El Calafate El Calafate Argentina

Funder

Centro de Investigación Biomédica en Red Fragilidad y Envejecimiento Saludable

European Regional Development Fund

Ministerio de Ciencia e Innovación

Publisher

Wiley

Subject

Orthopedics and Sports Medicine,Endocrinology, Diabetes and Metabolism

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/jbm4.10602

Reference77 articles.

1. Romosozumab Treatment in Postmenopausal Women with Osteoporosis

2. Romosozumab in Postmenopausal Women with Low Bone Mineral Density

3. A Randomized, Double‐Blind Phase 2 Clinical Trial of Blosozumab, a Sclerostin Antibody, in Postmenopausal Women with Low Bone Mineral Density

4. BPS804 Anti-Sclerostin Antibody in Adults With Moderate Osteogenesis Imperfecta: Results of a Randomized Phase 2a Trial

5. Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. CD97 inhibits osteoclast differentiation via Rap1a/ERK pathway under compression;International Journal of Oral Science;2024-02-04